Noteworthy Short Interest Filing: What Will Happen to Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) Next? The Stock Has Decline in Shorts

November 18, 2016 - By Ruchi Gupta   ·   0 Comments

Noteworthy Short Interest Filing: What Will Happen to Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) Next? The Stock Has Decline in Shorts

The stock of Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) registered a decrease of 1.3% in short interest. TTPH’s total short interest was 2.53 million shares in November as published by FINRA. Its down 1.3% from 2.56 million shares, reported previously. With 323,800 shares average volume, it will take short sellers 8 days to cover their TTPH’s short positions. The short interest to Tetraphase Pharmaceuticals Incorporated’s float is 7.96%. About 7,997 shares traded hands. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has declined 27.85% since April 18, 2016 and is downtrending. It has underperformed by 32.28% the S&P500.

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $144.33 million. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. It currently has negative earnings. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Insitutional Activity: The institutional sentiment increased to 1.12 in 2016 Q2. Its up 0.26, from 0.86 in 2016Q1. The ratio improved, as 18 funds sold all Tetraphase Pharmaceuticals Inc shares owned while 26 reduced positions. 14 funds bought stakes while 24 increased positions. They now own 21.31 million shares or 7.27% less from 22.99 million shares in 2016Q1.
Teachers has invested 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Connor Clark Lunn Management Ltd accumulated 0% or 17,500 shares. Dow Chemical De accumulated 0.03% or 65,000 shares. Huntington National Bank has invested 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Barclays Pcl holds 0% or 548 shares in its portfolio. Credit Suisse Ag holds 0% or 48,126 shares in its portfolio. Savings Bank Of Montreal Can has invested 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Aqr Mngmt Llc holds 34,732 shares or 0% of its portfolio. Bancorp Of America Corp De holds 0% or 12,406 shares in its portfolio. Rhenman & Ptnrs Asset Mgmt, a Sweden-based fund reported 300,000 shares. Nationwide Fund Advisors last reported 24,109 shares in the company. Wellington Mgmt Gp Ltd Liability Partnership accumulated 0% or 2.47 million shares. State Board Of Administration Of Florida Retirement, a Florida-based fund reported 19,717 shares. Legal & General Grp Plc owns 6,756 shares or 0% of their US portfolio. Gabelli Funds Limited Liability owns 120,000 shares or 0% of their US portfolio.

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Ratings Coverage

Out of 11 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 1 rate it a “Buy”, 0 “Sell”, while 10 “Hold”. This means 9% are positive. Tetraphase Pharmaceuticals has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Wednesday, September 9 by Wedbush. SunTrust upgraded the shares of TTPH in a report on Thursday, November 19 to “Buy” rating. The rating was downgraded by Robert W. Baird to “Neutral” on Wednesday, September 9. The firm has “Neutral” rating by Gabelli given on Friday, May 13. Stifel Nicolaus maintained it with “Buy” rating and $57 target price in Thursday, August 6 report. Needham maintained the stock with “Buy” rating in Thursday, August 6 report. The firm has “Hold” rating given on Wednesday, September 9 by Needham. The company was initiated on Tuesday, April 12 by BMO Capital Markets. The firm earned “Market Perform” rating on Wednesday, September 9 by JMP Securities. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, September 9.

TTPH Company Profile

Tetraphase Pharmaceuticals, Inc. (Tetraphase), incorporated on July 7, 2006, is a clinical-stage biopharmaceutical company. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The Firm also develops TP-6076 for multidrug-resistant Gram- negative infections.

More notable recent Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) news were published by: Marketwatch.com which released: “Tetraphase’s stock tumbles 21% to record low” on April 15, 2013, also Streetinsider.com with their article: “Tetraphase Pharma (TTPH) Announces Publication of IGNITE1 Data; Statistical …” published on November 17, 2016, Fool.com published: “Why Tetraphase Pharmaceuticals Inc Stock Was Annihilated Today” on September 09, 2015. More interesting news about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) were released by: Fool.com and their article: “Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015” published on January 11, 2016 as well as Globenewswire.com‘s news article titled: “Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” with publication date: August 04, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>